Coronary heart disease
Conditions
Interventions
Sponsors
Xiyuan Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria of healthy volunteers: 1. Age: 18-50 years old; 2.BMI between 18 and 24; 3. Not taking any medication for at least 2 weeks; 4. No bad habits, no smoking history; 5. No drinking within 72 hours; 6. Informed consent and voluntary signing of informed consent. Inclusion criteria for patients with angina pectoris and acute myocardial infarction: 1. patients clinically diagnosed with angina pectoris or type 1 acute myocardial infarction; 2. Men and women aged between 18 and 85; 3. Patients or their family members were informed of the study and signed the informed consent voluntarily.
Exclusion criteria
Exclusion criteria: Exclusion criteria of healthy volunteers: 1. History of cardiovascular, cerebrovascular, liver, lung, kidney, digestive, endocrine, metabolic, blood, immune system and systemic inflammatory diseases judged by researchers as clinically significant; 2. Patients with various malignant tumors or benign tumors affecting health; 3. Patients with other diseases that may affect platelet count and function in the past 2 weeks, such as upper respiratory tract infection; 4. Infectious or allergic diseases; 5. Mental patients; 6. Functional or organic menorrhagia, more than 80ml blood loss per menstrual cycle for 3 consecutive times; 7. Pregnant women. Exclusion criteria for patients with angina pectoris and acute myocardial infarction: 1. Patients with uncontrolled grade III hypertension (systolic blood pressure >=180mmHg and/or diastolic blood pressure >=110mmHg), severe cardiopulmonary insufficiency, serious arrhythmias, malignant tumors, serious primary diseases of liver, kidney or hematopoietic system, or other serious diseases affecting their survival (such as tumors) and psychiatric patients; 2. Combined with other clinical conditions that may increase the risk of bleeding, such as a history of major organ bleeding in the past six months (such as cerebral hemorrhage, upper gastrointestinal hemorrhage, etc.), decreased platelet count, abnormal coagulation function, and oral warfarin anticoagulant therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proteomics; | — |
Secondary
| Measure | Time frame |
|---|---|
| Platelet aggregation test; | — |
Countries
China
Contacts
Public ContactRui Gao
Outcome results
None listed